Zymeworks (ZYME) Stock Forecast & Price Target

Compare

526 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZYME Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Zymeworks

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZYME Stock 12 Month Forecast

Average Price Target

$23.80

▲(82.52%Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $23.80 with a high forecast of $30.00 and a low forecast of $13.00. The average price target represents a 82.52% change from the last price of $13.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","13":"$13","19":"$19","25":"$25","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13,19,25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.41,13.763076923076923,15.116153846153846,16.46923076923077,17.822307692307692,19.175384615384615,20.52846153846154,21.88153846153846,23.234615384615385,24.587692307692308,25.94076923076923,27.293846153846154,28.646923076923077,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.41,13.286153846153846,14.162307692307692,15.038461538461538,15.914615384615384,16.790769230769232,17.666923076923077,18.543076923076924,19.41923076923077,20.295384615384616,21.17153846153846,22.04769230769231,22.923846153846156,{"y":23.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.41,12.455384615384615,12.500769230769231,12.546153846153846,12.591538461538462,12.636923076923077,12.682307692307692,12.727692307692308,12.773076923076923,12.818461538461538,12.863846153846154,12.909230769230769,12.954615384615385,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.88,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$23.80

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

-0.31%

Downside

Reiterated

07/03/25

Zymeworks' overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. However, positive sentiment from the latest earnings call, driven by revenue growth and strategic partnerships, provides some optimism. Technical indicators show a positive short-term trend, but valuation remains unattractive due to ongoing losses.

Robert BurnsH.C. Wainwright

H.C. Wainwright

$13

Hold

-0.31%

Downside

Reiterated

07/03/25

Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts

Charles ZhuLifeSci Capital

LifeSci Capital

$30

Buy

130.06%

Upside

Reiterated

07/01/25

Zymeworks Gains Momentum with European Approval and Promising Financial Milestones for Zanidatamab

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$21→$28

Buy

114.72%

Upside

Reiterated

06/02/25

Zymeworks' Promising Clinical Developments and Strategic Positioning Justify Buy Rating

Brian ChengJ.P. Morgan

J.P. Morgan

$18

Buy

38.04%

Upside

Reiterated

05/30/25

Zymeworks' Zanidatamab: Promising Potential in HER2-Positive Cancer Treatment and Strategic Market Positioning Justify Buy Rating

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Initiated

05/20/25

Zymeworks: Buy Rating Driven by Innovative Pipeline and Strategic Partnerships

Andrew BerensLeerink Partners

Leerink Partners

$30

Buy

130.06%

Upside

Reiterated

05/09/25

Zymeworks's Promising Pipeline and Strategic Partnerships Drive Buy Rating

Unknown AnalystJefferies

Not Ranked

Jefferies

$24→$30

Buy

130.06%

Upside

Reiterated

03/14/25

Derek ArchilaWells Fargo

Wells Fargo

$14

Hold

7.36%

Upside

Reiterated

03/12/25

Zymeworks (ZYME) Gets a Hold from Wells Fargo

Yigal NochomovitzCiti

Citi

$18→$19

Buy

45.71%

Upside

Reiterated

03/06/25

Zymeworks (ZYME) PT Raised to $19 at CitiCiti analyst Yigal Nochomovitz raised the price target on Zymeworks (NASDAQ: ZYME) to $19.00 (from $18.00) while maintaining a Buy rating.

Jonathan MillerEvercore ISI

Evercore ISI

$12

Buy

-7.98%

Downside

Reiterated

03/06/25

Zymeworks (ZYME) Gets a Buy from Evercore ISI

David Martin PhDBloom Burton

Bloom Burton

$19.5

Buy

49.54%

Upside

Assigned

11/21/24

Zymeworks Gains Buy Rating Amid FDA Approval and Market Expansion Potential for Zanidatamab

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

-0.31%

Downside

Reiterated

07/03/25

Robert BurnsH.C. Wainwright

H.C. Wainwright

$13

Hold

-0.31%

Downside

Reiterated

07/03/25

Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts

Charles ZhuLifeSci Capital

LifeSci Capital

$30

Buy

130.06%

Upside

Reiterated

07/01/25

Zymeworks Gains Momentum with European Approval and Promising Financial Milestones for Zanidatamab

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$21→$28

Buy

114.72%

Upside

Reiterated

06/02/25

Zymeworks' Promising Clinical Developments and Strategic Positioning Justify Buy Rating

Brian ChengJ.P. Morgan

J.P. Morgan

$18

Buy

38.04%

Upside

Reiterated

05/30/25

Zymeworks' Zanidatamab: Promising Potential in HER2-Positive Cancer Treatment and Strategic Market Positioning Justify Buy Rating

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Initiated

05/20/25

Zymeworks: Buy Rating Driven by Innovative Pipeline and Strategic Partnerships

Andrew BerensLeerink Partners

Leerink Partners

$30

Buy

130.06%

Upside

Reiterated

05/09/25

Zymeworks's Promising Pipeline and Strategic Partnerships Drive Buy Rating

Unknown AnalystJefferies

Not Ranked

Jefferies

$24→$30

Buy

130.06%

Upside

Reiterated

03/14/25

Derek ArchilaWells Fargo

Wells Fargo

$14

Hold

7.36%

Upside

Reiterated

03/12/25

Zymeworks (ZYME) Gets a Hold from Wells Fargo

Yigal NochomovitzCiti

Citi

$18→$19

Buy

45.71%

Upside

Reiterated

03/06/25

Zymeworks (ZYME) PT Raised to $19 at CitiCiti analyst Yigal Nochomovitz raised the price target on Zymeworks (NASDAQ: ZYME) to $19.00 (from $18.00) while maintaining a Buy rating.

Jonathan MillerEvercore ISI

Evercore ISI

$12

Buy

-7.98%

Downside

Reiterated

03/06/25

Zymeworks (ZYME) Gets a Buy from Evercore ISI

David Martin PhDBloom Burton

Bloom Burton

$19.5

Buy

49.54%

Upside

Assigned

11/21/24

Zymeworks Gains Buy Rating Amid FDA Approval and Market Expansion Potential for Zanidatamab

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zymeworks

1 Month

xxx

Success Rate

12/20 ratings generated profit

Average Return

+3.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.03% per trade.

3 Months

xxx

Success Rate

11/15 ratings generated profit

Average Return

+12.37%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +12.37% per trade.

1 Year

Yigal NochomovitzCiti

Success Rate

12/15 ratings generated profit

Average Return

+39.35%

reiterated a buy rating 4 months ago

Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +39.35% per trade.

2 Years

xxx

Success Rate

13/15 ratings generated profit

Average Return

+67.56%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +67.56% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZYME Analyst Recommendation Trends

Rating

Jan 25

Mar 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZYME has received 8 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ZYME average Analyst price target in the past 3 months is 23.80.

Each month's total comprises the sum of three months' worth of ratings.

ZYME Financial Forecast

ZYME Earnings Forecast

Next quarter’s earnings estimate for ZYME is -$0.49 with a range of -$0.58 to -$0.38. The previous quarter’s EPS was -$0.30. ZYME beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year ZYME has Outperformed its overall industry.

ZYME Sales Forecast

Next quarter’s sales forecast for ZYME is $16.88M with a range of $10.00M to $27.00M. The previous quarter’s sales results were $27.11M. ZYME beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year ZYME has Outperformed its overall industry.

ZYME Stock Forecast FAQ

What is ZYME’s average 12-month price target, according to analysts?

Based on analyst ratings, Zymeworks Inc’s 12-month average price target is 23.80.

What is ZYME’s upside potential, based on the analysts’ average price target?

Zymeworks Inc has 82.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZYME a Buy, Sell or Hold?

Zymeworks Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Zymeworks Inc’s price target?

The average price target for Zymeworks Inc is 23.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $13.00. The average price target represents 82.52% Increase from the current price of $13.04.

What do analysts say about Zymeworks Inc?

Zymeworks Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ZYME?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zymeworks (ZYME) Stock Forecast & Price Target

ZYME Analyst Ratings

ZYME Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zymeworks

ZYME Analyst Recommendation Trends

ZYME Financial Forecast

ZYME Earnings Forecast

ZYME Sales Forecast

ZYME Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts